Clovis Oncology, Inc. (NASDAQ:CLVS) traded at $7 at last check on Monday, Sep 14, making an upward move of 15.89% on its previous day’s price.
Looking at the stock we see that its previous close was $6.04 and the beta (5Y monthly) reads 2.22 with the day’s price range being $6.26 – 7.07. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, CLVS has a high of $17.37 and a low of $2.93. The company’s stock has gained about 43.15% over that past 30 days.
Clovis has a market cap of $585.27 Million and is expected to release its quarterly earnings report on Nov 05, 2020- Nov 09, 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the CLVS stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$1, with the EPS growth for the year raised at -$4.31 for 2020 and -$2.55 for next year. These figures represent -0.42% and at -0.41% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $42.93 Million, with a low of $40.68 Million and a high of $45.5 Million. The median projection represents growth adding up to 14.2% compared to sales earnings for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecasts for 2020 are expected to hit $172.92 Million, or +20.9% up from figures reported last year.
There have been 1 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the CLVS stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of Hold.
Based on estimates by 8 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 4 have rated the Clovis Oncology, Inc. (CLVS) stock as a Hold, while 1 rate it as a Buy. None analysts rate it as outperform while 1 of them rated it as underperform, whereas 2 suggests the stock as a Sell. The stock has an overall rating of Hold and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the CLVS stock currently stands at 0, and the current price level is 31.67% off its SMA20 and 20.48% from its 50-day simple moving average. The RSI (14) is pointing at 71.44 while the volatility over the past week is 1007% and drops to 8.23% over the past one month. The beta value is 2.22, while the average true range (ATR) is currently pointing at 0.47. The average price target for the stock over the next 12 months is $8.67, with the estimates having a low of $4 and a high of $23. These price ends are -42.86% and +228.57% off the current price level respectively, although investors could be excited at the prospect of a -14.29% if the CLVS share price touches on the median price of $6.
Let’s briefly compare Clovis (CLVS) stock to its peers. We find that today’s price change of +15.89% and +29.39% over the past 12 months for CLVS betters that of Amgen Inc (AMGN), which has seen its stock price rise 1.46% in the latest trading session and is +26.23% over the last one year. Another of its peers Bristol-Myers Squibb Company (BMY) has climbed 1.2% today, and is +20.78% up over the past year, while Gilead Sciences Inc (GILD) is also up 15.89% yet its price remains in the green at 29.39% over the same period. Amgen has a P/E ratio of 20.16 compared to Clovis 0 and Bristol-Myers 0. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 1.27% and 1.18%, respectively, in early deals.
Coming back to Clovis Oncology, Inc. (NASDAQ:CLVS), we note that the average 3-month trading volume was 4.55 Million, while that of the preceding 10-day period stands at 5.21 Million. Current shares outstanding are 88.2 Million.
According to data from Thomson Reuters, insiders hold 2.27% of the company’s shares while institutions hold 48.46%. The data shows that short shares as of August 30, 2020, stood at 36.57 Million at a short ratio of 6.9. This represents a 41.46% Short interest in Shares outstanding on August 30, 2020. Shares short rose in August from the previous month at 33.92 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -32.85% down in year-to-date price movement.